GLOBAL (NOW INCLUDING JAPAN)
CO-DEVELOPMENT, KNOW-HOW AND SUPPLY
AGREEMENT FOR GALANTAMINE
SHIRE INTERNATIONAL LICENSING BV
JANSSEN PHARMACEUTICA NV
THIS AGREEMENT is made this 22nd day of July One Thousand nine hundred and ninety nine by and between
Shire International Licensing BV of Fredericksplem 42, P.O. Box 545, 1000 AM Amsterdam, Netherlands
("Shire") and Janssen Pharmaceutica NV of Turnhoustseweg 30, B2340 Beerse, Belgium ("Janssen").
WHEREAS Shire and Janssen entered into a Co-Development, Know-How and Supply Agreement for
galantamine on 30 November 1995 ("the Global Agreement").
WHEREAS Janssen concluded an arrangement with A+, Science Invest AB, a Swedish corporation ("A+") in
relation to the development of galantamine for Obstructive Sleep Apnoea on 29 January 1999 ("the A+
Agreement") and Janssen and Shire now wish to extend the arrangements in the Global Agreement to the
development of galantamine for use in the treatment of Obstructive Sleep Apnoea.
WHEREAS Janssen and Shire now wish to extend arrangements in the Global Agreement to the development
and exploitation of galantamine in Japan for Alzheimer's disease and Chronic Fatigue Syndrome.
NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:
Clause 1 Amendments to the Global Agreement
It is hereby agreed that the Global Agreement be amended as follows:
1.1 In Clause 1 the following definitions shall be amended as follows:
(a) in Clause 1.24 there shall be inserted after the word "Thailand"
the word "Japan;
(b) Clause 1.25 shall be deleted in its entirety and there shall be
inserted in substitution therefor:
"1.25 "Licensed Product(s)" any product containing Galantamine
(whether Natural Galantamine and/or
Synthetic Galantamine) which is used